An exploratoly study to evaluate biomarkers in cell free DNA of "Sequential therapy from afatinib to osimertinib for EGFR mutant non small cell lung cancer: a multicenter prospective observational study (Gio Tag Japan)".
Not Applicable
Recruiting
- Conditions
- non-small cell lung cancer(EGFR mutation positive)
- Registration Number
- JPRN-UMIN000043235
- Lead Sponsor
- HANSHIN Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 93
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the correlation between the presence or absence of compound mutations in cfDNA and the duration of treatment with sequential therapy from afatinib to osimertinib
- Secondary Outcome Measures
Name Time Method 1) To evaluate the correlation between the presence or absence of compound mutations in cfDNA at resistance to afatinib and the duration of afatinib treatment 2) To evaluate the correlation between the presence or absence of compound mutations in cfDNA before afatinib treatment and the duration of osimertinib treatment 3) To evaluate the correlation between the presence or absence of compound mutations in cfDNA and overall survival 4) To evaluate changes in compound mutations before afatinib and at resistance